Fusion Pharma LLC   Report issue

For profit Phase 1 Phase 2
Founded: Moscow Russian Federation (2010)
Status: Acquired by Arpida AG (2009) → now Evolva SA (2009)

Organization Overview

First Clinical Trial
2016
NCT02885766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fusion Pharmaceuticals | Fusion Pharmaceuticals Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 10